|
Delayed
Nasdaq
01:00:00 27/02/2026 +04
|
5-day change | 1st Jan Change | ||
| 72.82 USD | +0.03% |
|
-.--% | +0.96% |
| 08-20 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| 08-13 | Atrium Therapeutics Earns Another $15 Million Milestone Payment From Bristol Myers Squibb | MT |
| Market Cap | 11.3B 9.75B 9.18B 8.37B 15.64B 1,067B 15.75B 109B 42.19B 546B 42.43B 41.5B 1,792B | P/E 2024 |
-10.1x | P/E 2025 | -14.5x |
|---|---|---|---|---|---|
| Enterprise Value | 9.65B 8.33B 7.84B 7.15B 13.36B 912B 13.46B 92.85B 36.03B 466B 36.24B 35.45B 1,531B | EV / Sales 2024 |
181x | EV / Sales 2025 | 492x |
| Free-Float |
10.55% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript : Avidity Biosciences, Inc.
| 1 day | +0.03% | ||
| Current year | +0.96% |
| Current year | 72 |  | 73.06 |
| 1 year | 35.7 | | 73.06 |
| 3 years | 4.82 | | 73.06 |
| 5 years | 4.82 | | 73.06 |
| 10 years | 4.82 | | 73.06 |
| Manager | Title | Age | Since |
|---|---|---|---|
John McKenna
PSD | President | - | 27/02/2026 |
Eduard Marti
TRE | Treasurer | - | 27/02/2026 |
Jaime S. Huertas
SEC | Corporate Secretary | - | 27/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jaime S. Huertas
BRD | Director/Board Member | - | 27/02/2026 |
Eduard Marti
BRD | Director/Board Member | - | 27/02/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/02/26 | Issuer sale | Director | 110,073 | 0.0766% | ||
| 27/02/26 | Issuer sale | Chief Technology Officer | 547,865 | 0.3814% | ||
| 27/02/26 | Issuer sale | General Counsel | 302,054 | 0.2103% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | -.--% | +54.18% | +814.82% | 11.3B | |
| -1.19% | +4.07% | +49.10% | +2.15% | 85.08B | |
| -3.94% | +2.12% | +506.24% | +33.32% | 60.21B | |
| +0.95% | +1.77% | -15.77% | -34.78% | 59.71B | |
| -1.60% | -7.63% | -3.65% | +31.05% | 51.1B | |
| -0.18% | -0.81% | +8.96% | +169.33% | 48.73B | |
| +0.92% | +1.51% | +58.76% | -15.57% | 32.9B | |
| -0.69% | +0.10% | +47.04% | +102.07% | 26.11B | |
| +0.79% | -6.56% | -2.56% | +192.31% | 22.6B | |
| +1.14% | -1.62% | +64.24% | +113.25% | 16.42B | |
| Average | -0.40% | -1.26% | +76.65% | +140.80% | 41.42B | |
| Weighted average by Cap. | -0.81% | -0.76% | +93.53% | +66.44% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 10.9M 9.4M 8.86M 8.07M 15.08M 1.03B 15.19M 105M 40.69M 526M 40.92M 40.02M 1.73B | 18.76M 16.18M 15.24M 13.89M 25.96M 1.77B 26.15M 180M 70.03M 906M 70.43M 68.89M 2.98B |
| Net income | -322M -278M -262M -239M -446M -30.45B -449M -3.1B -1.2B -15.57B -1.21B -1.18B -51.13B | -685M -591M -556M -507M -948M -64.67B -955M -6.59B -2.56B -33.07B -2.57B -2.51B -109B |
| Net Debt | -1.49B -1.29B -1.21B -1.11B -2.07B -141B -2.08B -14.38B -5.58B -72.19B -5.61B -5.49B -237B | -1.65B -1.42B -1.34B -1.22B -2.28B -156B -2.3B -15.85B -6.15B -79.58B -6.19B -6.05B -261B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RNA Stock
Select your edition
All financial news and data tailored to specific country editions
